Summary: 

• The global gene panel market size reached USD 1,153.2 Million in 2024.
• The market is expected to reach USD 3,775.0 Million by 2033, exhibiting a growth rate (CAGR) of 14.08%  during 2025-2033.
• North America leads the market, accounting for the largest gene panel market share.
• Test kits account for the majority of the market share in the products and services segment as they provide a complete solution for genetic testing, allowing laboratories and healthcare providers to perform multiple assays effectively. 
• Amplicon-based approach holds the largest share in the gene panel industry.
• Predesigned gene panels remain a dominant segment in the market as they streamline the testing process for clinicians by offering ready-to-use panels for different genetic conditions, ultimately conserving time and resources.
• Cancer risk represents the leading application segment.
• Academic and research institutes clearly dominate the market, as they perform extensive research on genetic diseases and utilize gene panels for a variety of studies, creating substantial demand for these products.
• The increasing demand for personalized medicine s a primary driver of the gene panel market.
• The growing applications in oncology is propelling the gene panel market.

Increasing Adoption of Personalized Medicine

By 2025, the gene panel market will likely surge. This is due to the growing use of personalized medicine. As healthcare moves to more personalized treatments, the demand for gene panels is soaring. These panels analyze multiple genes at once. They are key to finding genetic factors that affect disease progression and treatment responses. Specifically, genetic testing for cancer, heart disease, and rare disorders will drive this trend. By 2024, more patients will benefit from treatments based on their genes. This will increase the demand for advanced genetic tests. This trend in personalized healthcare will improve medical treatment. It will create new markets for companies in gene panel tech. This is especially true for those with low-cost, high-throughput solutions.

Expansion of Genomic Data and Bioinformatics Integration

By 2025, genomic data and bioinformatics will reshape the gene panel market. New sequencing technologies are improving our ability to process large genetic datasets. They are expected to drastically reduce the costs of gene panel testing. The rise of bioinformatics platforms for data analysis is a key factor driving the market's growth. By 2024, AI and machine learning will improve bioinformatics tools. They will enable faster, more accurate analysis of genetic data. This integration is key to making gene panels more accessible. It will help both healthcare providers and patients. It will boost their use in clinical and research settings. Gene panels will become vital for diagnosing genetic disorders. They will also help identify people at risk for certain diseases. This will boost the use of genomics in precision medicine.

Government and Healthcare Investments in Genomic Research

Governments and healthcare groups are investing more in genomic research and genetic testing. By 2025, these investments will greatly boost the gene panel market. Governments worldwide, including in North America and Europe, will likely fund policies to use genomic technologies in healthcare. Funding for research into genetic diseases and cancer is expected to expand what gene panels can diagnose and treat. By 2024, more countries are expected to fund public health initiatives on genomic medicine. This will make gene panel testing a more common diagnostic tool in clinical practices. This support will boost the market. It will make gene panel testing cheaper and more accessible. This will drive wider use in healthcare.

Request Sample For PDF Report: https://www.imarcgroup.com/gene-panel-market/requestsample

Report Segmentation:

The report has segmented the market into the following categories:

Products and Services Insights:

• Test Kits
• Testing Services

Test kits account for the majority of shares as they offer a comprehensive solution for genetic testing, enabling laboratories and healthcare providers to conduct multiple assays efficiently.

Technique Insights:

• Amplicon-based Approach
• Hybridization-based Approach

Amplicon-based approach dominates the market due to its ability to provide targeted sequencing of specific regions of interest, making it popular for high-throughput gene analysis.

Design Insights:

• Predesigned Gene Panel
• Customized Gene Panel

Predesigned gene panels represent the majority of shares as they simplify the testing process for clinicians by providing ready-to-use panels for various genetic conditions, thereby saving time and resources.

Application Insights:

• Cancer Risk Assessment
• Diagnosis of Congenital Diseases
• Pharmacogenetics
• Others

Cancer risk assessment holds the majority of shares as an increasing number of patients and healthcare providers are prioritizing genetic testing to identify inherited cancer risks and tailor preventive strategies accordingly.

End User Insights:

• Academic and Research Institutes
• Hospital and Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies

Academic and research institutes exhibit a clear dominance as they conduct extensive research on genetic diseases and utilize gene panels for various studies, driving significant demand for these products.

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America holds the leading position owing to a large market for gene panel driven by its advanced healthcare infrastructure, high investment in genetic research, and widespread adoption of personalized medicine practices.

Top Gene Panel Market Leaders:

• Agilent Technologies Inc.
• BGI Genomics Co. Ltd. (BGI Group)
• Eurofins Scientific SE
• F. Hoffmann-La Roche AG
• Genewiz LLC (Azenta Inc.)
• Illumina Inc.
• Integrated DNA Technologies Inc. (Danaher Corporation)
• Novogene Co. Ltd.
• Qiagen N.V.
• Thermo Fisher Scientific Inc.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.